LYL1 and acute lymphoblastic leukemia: We also tested AZD7762 and FK866 in three of the PDX-expanded human T-ALL cases, including two from the TAL1/LMO1 subtype and one from the LYL1/LMO2 subtype, and both agents were effective in the nanomolar range (Fig 1B, S2 Fig, S3 Fig, and S4 Table).